DMPI, he recibido este mail...
Good Morning,
Please find attached the press release DelMar Pharmaceuticals issued today announcing the presentation by researchers from the University of British Columbia (UBC) and Vancouver Prostate Centre (VPC) regarding new data on VAL-083's unique mechanism of action.
These new data were presented on November 9th by UBC and VPC researchers in a poster entitled, "Exploring the Molecular Mechanisms of Dianhydrogalactitol (VAL-083) in Cancer Treatment," at the 2015 Canadian Cancer Research Conference of the Canadian Cancer Research Alliance (CCRA).
Results indicate that treatment of cancer cells by VAL-083 induces phosphorylation of H2AX, a hallmark of double-strand DNA breaks. H2AX is a histone involved in the CHK2 checkpoint activation pathway, a key component of the body's immune response to DNA damage resulting in down-stream signaling ultimately resulting in apoptosis.
The study results also demonstrate a pattern of durability in the DNA lesions caused by VAL-083, which suggest that VAL-083 is effective at modifying tumor cells and may halt tumor progression by inhibiting natural cellular repair processes and further validate the differentiation and potential superiority of VAL-083 versus other chemotherapeutic agents.
These data are in line with DelMar's approach to leverage significant historical clinical data from prior NCI-sponsored studies; which, when juxtaposed against new understanding of VAL-083's biological mechanism, provide an opportunity to accelerate the development of VAL-083 as a new 'personalized-medicine' therapy for cancer patients with limited treatment options.
We will continue to explore the signaling pathways involved in VAL-083 to help focus our drug development efforts on patients with cancer who would most benefit from VAL-083 treatment.
The research presented at the 2015 Cancer Research Conference was funded in part by financial contributions from Canada's National Research Council's Industrial Research Assistance Program (NRC-IRAP) and Mitacs, a Canadian Network of Centres of Excellence, dedicated to supporting scientific and industrial research.
The poster from the conference may be found on DelMar's website under http://www.delmarpharma.com/scientific-publications.html.